Filing Details

Accession Number:
0001437749-16-043586
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-20 16:30:15
Reporting Period:
2016-12-16
Filing Date:
2016-12-20
Accepted Time:
2016-12-20 16:30:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1586049 Oxford Immunotec Global Plc OXFD In Vitro & In Vivo Diagnostic Substances (2835) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1592286 Peter Wrighton-Smith C/O Oxford Immunotec Global Plc
94C Innovation Drive
Abingdon, Oxfordshire X0 OX14 4RZ
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2016-12-16 7,052 $0.81 450,366 No 4 M Direct
Ordinary Shares Disposition 2016-12-16 7,052 $15.07 443,314 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2016-12-16 7,052 $0.00 7,052 $0.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
101,438 2020-02-17 No 4 M Direct
Footnotes
  1. The original exercise price of these options was priced in GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
  3. The price reported for the sales on December 16, 2016 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  4. Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.